Ivermectin Misses Goal in PIII COVID-19 Trial: Kowa

September 27, 2022
Kowa said on September 26 that the antiparasitic agent ivermectin failed to meet the primary endpoint in a PIII study for the treatment of COVID-19. The company plans to terminate the program, while looking into the drug’s potential in other...read more